Lilly ‘Ghostwrote’ Articles to Market Drug, Files Say

From Bloomberg: Link

Lilly ‘Ghostwrote’ Articles to Market Drug, Files Say (Update2)

By Elizabeth Lopatto, Jef Feeley and Margaret Cronin Fisk

June 11 (Bloomberg) -- Eli Lilly & Co. officials wrote medical journal studies about the antipsychotic Zyprexa and then asked doctors to put their names on the articles, a practice called “ghostwriting,” according to unsealed company files.

Lilly employees also compiled a guide to hiring scientists to write favorable articles, complained to journal editors when publication was delayed and submitted rejected articles to other outlets, according to documents filed in drug-overpricing suits against the Indianapolis-based company, the largest manufacturer of psychiatric medicines.

Drugmakers’ use of ghostwriters has created “a huge body of medical literature that society can’t trust,” said Carl Elliott, a University of Minnesota bioethicist who has written about the practice. "

Also see this article.